ISSUE 1525
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
The FDA has approved brodalumab (Siliq – Valeant), an injectable human interleukin (IL)-17A receptor antagonist, for treatment of adults with moderate to severe plaque psoriasis who have failed to respond to other systemic therapies. Brodalumab is the third IL-17A antagonist to be approved in the US for this indication; secukinumab (Cosentyx) and ixekizumab (Taltz) were approved earlier.1,2
STANDARD TREATMENT — Plaque psoriasis is a chronic, inflammatory, immune-mediated skin condition. Mild to moderate psoriasis is generally treated with topical corticosteroids. Topical vitamin D analogs and the retinoid tazarotene (Tazorac, and others) are alternatives that can be used alone or in combination with topical corticosteroids.3 For patients with moderate to severe disease, systemic options include
... more- Secukinumab (Cosentyx) for psoriasis. Med Lett Drugs Ther 2015; 57:45.
- Ixekizumab (Taltz) – a second IL-17A inhibitor for psoriasis. Med Lett Drugs Ther 2016; 58:59.
- Calcipotriene/betamethasone foam (Enstilar) for psoriasis. Med Lett Drugs Ther 2016; 58:48.
- Drugs for psoriasis. Med Lett Drugs Ther 2015; 57:81.
- TN Canavan et al. Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol 2016; 17:33.
- A Chiricozzi et al. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. Expert Opin Drug Saf 2016; 15:1653.

Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1525b
Electronic, downloadable article - $45